SI9820009A - Novi etilaminski derivati - Google Patents
Novi etilaminski derivati Download PDFInfo
- Publication number
- SI9820009A SI9820009A SI9820009A SI9820009A SI9820009A SI 9820009 A SI9820009 A SI 9820009A SI 9820009 A SI9820009 A SI 9820009A SI 9820009 A SI9820009 A SI 9820009A SI 9820009 A SI9820009 A SI 9820009A
- Authority
- SI
- Slovenia
- Prior art keywords
- compound
- carbon atoms
- compounds
- propylaminopentane
- ring
- Prior art date
Links
- 150000003947 ethylamines Chemical class 0.000 title claims description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 215
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 46
- -1 bicyclic compound Chemical class 0.000 claims abstract description 30
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims abstract description 26
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 23
- 239000003814 drug Substances 0.000 claims abstract description 22
- 229940079593 drug Drugs 0.000 claims abstract description 18
- 239000001257 hydrogen Substances 0.000 claims abstract description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 13
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims abstract description 13
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000002253 acid Substances 0.000 claims abstract description 12
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000000935 antidepressant agent Substances 0.000 claims abstract description 9
- 229940005513 antidepressants Drugs 0.000 claims abstract description 9
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 9
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 claims abstract description 8
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 8
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 7
- 125000003118 aryl group Chemical group 0.000 claims abstract description 7
- 150000002367 halogens Chemical class 0.000 claims abstract description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 7
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 5
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims abstract description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 3
- GKNKHAOHVXOYDS-UHFFFAOYSA-N 1-naphthalen-2-yl-n-propylpentan-2-amine Chemical compound C1=CC=CC2=CC(CC(CCC)NCCC)=CC=C21 GKNKHAOHVXOYDS-UHFFFAOYSA-N 0.000 claims description 5
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 4
- MHURHAPIMANEFT-UHFFFAOYSA-N 1-(1,3-benzodioxol-4-yl)-n-propylpentan-2-amine Chemical compound CCCNC(CCC)CC1=CC=CC2=C1OCO2 MHURHAPIMANEFT-UHFFFAOYSA-N 0.000 claims description 2
- LJHIBIVAYHQPBT-UHFFFAOYSA-N 1-(1-benzofuran-2-yl)-n-propylpentan-2-amine Chemical compound C1=CC=C2OC(CC(CCC)NCCC)=CC2=C1 LJHIBIVAYHQPBT-UHFFFAOYSA-N 0.000 claims description 2
- OQTWGSLVDILQOQ-UHFFFAOYSA-N 1-(1h-indol-3-yl)-n-propylpentan-2-amine Chemical compound C1=CC=C2C(CC(CCC)NCCC)=CNC2=C1 OQTWGSLVDILQOQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 4
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 claims 2
- UGCBTMHNXZSDGW-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)-n-propylpentan-2-amine Chemical compound CCCNC(CCC)CC1=CC=C2OCOC2=C1 UGCBTMHNXZSDGW-UHFFFAOYSA-N 0.000 claims 1
- RJQCBJFDFFREPG-UHFFFAOYSA-N 1-(1h-indol-4-yl)-n-propylpentan-2-amine Chemical compound CCCNC(CCC)CC1=CC=CC2=C1C=CN2 RJQCBJFDFFREPG-UHFFFAOYSA-N 0.000 claims 1
- XSXBOIUXADABRE-UHFFFAOYSA-N 1-(1h-indol-6-yl)-n-propylpentan-2-amine Chemical compound CCCNC(CCC)CC1=CC=C2C=CNC2=C1 XSXBOIUXADABRE-UHFFFAOYSA-N 0.000 claims 1
- OCIDETNEPPTCDV-UHFFFAOYSA-N 1-(6-methoxynaphthalen-2-yl)-n-propylpentan-2-amine Chemical compound C1=C(OC)C=CC2=CC(CC(CCC)NCCC)=CC=C21 OCIDETNEPPTCDV-UHFFFAOYSA-N 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000000506 psychotropic effect Effects 0.000 claims 1
- 229940001470 psychoactive drug Drugs 0.000 abstract description 10
- 239000004089 psychotropic agent Substances 0.000 abstract description 10
- 230000000694 effects Effects 0.000 description 52
- 238000000034 method Methods 0.000 description 43
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 40
- 238000000921 elemental analysis Methods 0.000 description 38
- 239000000243 solution Substances 0.000 description 38
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 23
- 238000003786 synthesis reaction Methods 0.000 description 23
- 239000000203 mixture Substances 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- 241000700159 Rattus Species 0.000 description 19
- 150000003943 catecholamines Chemical class 0.000 description 19
- 235000002639 sodium chloride Nutrition 0.000 description 16
- 239000000155 melt Substances 0.000 description 13
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 12
- 102000010909 Monoamine Oxidase Human genes 0.000 description 11
- 108010062431 Monoamine oxidase Proteins 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 238000009739 binding Methods 0.000 description 10
- 230000001143 conditioned effect Effects 0.000 description 10
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 10
- 210000003568 synaptosome Anatomy 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229960005333 tetrabenazine Drugs 0.000 description 9
- 208000020369 Polymerase proofreading-related adenomatous polyposis Diseases 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 229960002748 norepinephrine Drugs 0.000 description 8
- 229940076279 serotonin Drugs 0.000 description 8
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 8
- 210000000133 brain stem Anatomy 0.000 description 7
- 239000012280 lithium aluminium hydride Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 6
- NOOYIVIUEHDMSF-PKLMIRHRSA-N (2r)-1-phenyl-n-(3-phenylpropyl)propan-2-amine;hydrochloride Chemical compound Cl.C([C@@H](C)NCCCC=1C=CC=CC=1)C1=CC=CC=C1 NOOYIVIUEHDMSF-PKLMIRHRSA-N 0.000 description 6
- 206010000117 Abnormal behaviour Diseases 0.000 description 6
- 229940124810 Alzheimer's drug Drugs 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 6
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000011514 reflex Effects 0.000 description 6
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical class NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 210000001772 blood platelet Anatomy 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 229960003638 dopamine Drugs 0.000 description 5
- 230000028023 exocytosis Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 210000001577 neostriatum Anatomy 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- UDZCSBYRWFJKHP-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)pentan-2-one Chemical compound CCCC(=O)CC1=CC=C2OCOC2=C1 UDZCSBYRWFJKHP-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 230000000768 catecholaminergic effect Effects 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000012442 inert solvent Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 239000008055 phosphate buffer solution Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 4
- 229960003946 selegiline Drugs 0.000 description 4
- 239000000021 stimulant Substances 0.000 description 4
- 210000003523 substantia nigra Anatomy 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 229960003732 tyramine Drugs 0.000 description 4
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010029350 Neurotoxicity Diseases 0.000 description 3
- 230000037007 arousal Effects 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 230000000035 biogenic effect Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 210000000627 locus coeruleus Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000002040 relaxant effect Effects 0.000 description 3
- 230000003578 releasing effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000011800 void material Substances 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- YICUJLBPMDWZNV-BTJKTKAUSA-N (z)-but-2-enedioic acid;1-naphthalen-2-yl-n-propylpentan-2-amine Chemical compound OC(=O)\C=C/C(O)=O.C1=CC=CC2=CC(CC(CCC)NCCC)=CC=C21 YICUJLBPMDWZNV-BTJKTKAUSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- DPADFICLBGFSJM-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)-n-butylpentan-2-amine Chemical compound CCCCNC(CCC)CC1=CC=C2OCOC2=C1 DPADFICLBGFSJM-UHFFFAOYSA-N 0.000 description 2
- VKDJCTGXHLFZDP-UHFFFAOYSA-N 1-naphthalen-2-ylpentan-2-amine Chemical compound C1=CC=CC2=CC(CC(N)CCC)=CC=C21 VKDJCTGXHLFZDP-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 235000019743 Choline chloride Nutrition 0.000 description 2
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 230000003185 calcium uptake Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 2
- 229960003178 choline chloride Drugs 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 2
- 229940080818 propionamide Drugs 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- ZZJYIKPMDIWRSN-TZBSWOFLSA-N (+)-butaclamol Chemical compound C12=CC=CC=C2CCC2=CC=CC3=C2[C@@H]1CN1CC[C@@](C(C)(C)C)(O)C[C@@H]13 ZZJYIKPMDIWRSN-TZBSWOFLSA-N 0.000 description 1
- AGJAUFUNZWHLKE-UHFFFAOYSA-N (2E,4E)-N-isobutyl-2,4-tetradecadienamide Natural products CCCCCCCCCC=CC=CC(=O)NCC(C)C AGJAUFUNZWHLKE-UHFFFAOYSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- YADPESXDKQIWLE-BTJKTKAUSA-N (z)-but-2-enedioic acid;1-naphthalen-1-yl-n-propylpentan-2-amine Chemical compound OC(=O)\C=C/C(O)=O.C1=CC=C2C(CC(CCC)NCCC)=CC=CC2=C1 YADPESXDKQIWLE-BTJKTKAUSA-N 0.000 description 1
- KEIFWROAQVVDBN-UHFFFAOYSA-N 1,2-dihydronaphthalene Chemical compound C1=CC=C2C=CCCC2=C1 KEIFWROAQVVDBN-UHFFFAOYSA-N 0.000 description 1
- BTKOXEBCZJJWDC-UHFFFAOYSA-N 1-(1,3-benzodioxol-4-yl)-n-propylpentan-2-amine;hydrochloride Chemical compound Cl.CCCNC(CCC)CC1=CC=CC2=C1OCO2 BTKOXEBCZJJWDC-UHFFFAOYSA-N 0.000 description 1
- HJVFQQAVWDDJRL-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)-n-butylpentan-2-amine;hydrochloride Chemical compound Cl.CCCCNC(CCC)CC1=CC=C2OCOC2=C1 HJVFQQAVWDDJRL-UHFFFAOYSA-N 0.000 description 1
- AXXXTXLCPXZYSH-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)-n-propylpentan-2-amine;hydrochloride Chemical compound Cl.CCCNC(CCC)CC1=CC=C2OCOC2=C1 AXXXTXLCPXZYSH-UHFFFAOYSA-N 0.000 description 1
- BWUFCVGRQFOTOA-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)pentan-2-amine Chemical compound CCCC(N)CC1=CC=C2OCOC2=C1 BWUFCVGRQFOTOA-UHFFFAOYSA-N 0.000 description 1
- FKBJXQNBMJWBSG-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)pentan-2-amine;hydrochloride Chemical compound Cl.CCCC(N)CC1=CC=C2OCOC2=C1 FKBJXQNBMJWBSG-UHFFFAOYSA-N 0.000 description 1
- GKKNDWKXWAVGOK-UHFFFAOYSA-N 1-(1-benzofuran-2-yl)-n-propylpentan-2-amine;hydrochloride Chemical compound Cl.C1=CC=C2OC(CC(CCC)NCCC)=CC2=C1 GKKNDWKXWAVGOK-UHFFFAOYSA-N 0.000 description 1
- YPGQWSNMHMFLCW-UHFFFAOYSA-N 1-(1-benzothiophen-2-yl)-n-propylpentan-2-amine;hydrochloride Chemical compound Cl.C1=CC=C2SC(CC(CCC)NCCC)=CC2=C1 YPGQWSNMHMFLCW-UHFFFAOYSA-N 0.000 description 1
- SLHAYUWXHFACJY-UHFFFAOYSA-N 1-(1-benzothiophen-3-yl)-n-propylpentan-2-amine;hydrochloride Chemical compound Cl.C1=CC=C2C(CC(CCC)NCCC)=CSC2=C1 SLHAYUWXHFACJY-UHFFFAOYSA-N 0.000 description 1
- RCTMUNNKMPIYLB-UHFFFAOYSA-N 1-(1h-indol-2-yl)-n-propylpentan-2-amine;hydrochloride Chemical compound Cl.C1=CC=C2NC(CC(CCC)NCCC)=CC2=C1 RCTMUNNKMPIYLB-UHFFFAOYSA-N 0.000 description 1
- WKUBZHVHXQWIMX-UHFFFAOYSA-N 1-(1h-indol-3-yl)-n-propylpentan-2-amine;hydrochloride Chemical compound Cl.C1=CC=C2C(CC(CCC)NCCC)=CNC2=C1 WKUBZHVHXQWIMX-UHFFFAOYSA-N 0.000 description 1
- JHUVGQKDCGOEJB-UHFFFAOYSA-N 1-(1h-indol-4-yl)-n-propylpentan-2-amine;hydrochloride Chemical compound Cl.CCCNC(CCC)CC1=CC=CC2=C1C=CN2 JHUVGQKDCGOEJB-UHFFFAOYSA-N 0.000 description 1
- XHIFSFDJPVXPLA-UHFFFAOYSA-N 1-(1h-indol-6-yl)-n-propylpentan-2-amine;hydrochloride Chemical compound Cl.CCCNC(CCC)CC1=CC=C2C=CNC2=C1 XHIFSFDJPVXPLA-UHFFFAOYSA-N 0.000 description 1
- VLIVVVDMPJNOPU-UHFFFAOYSA-N 1-(1h-indol-7-yl)-n-propylpentan-2-amine Chemical compound CCCNC(CCC)CC1=CC=CC2=C1NC=C2 VLIVVVDMPJNOPU-UHFFFAOYSA-N 0.000 description 1
- YXRBVSPNIQKGLW-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-n-propylpentan-2-amine;hydrochloride Chemical compound Cl.O1CCOC2=CC(CC(CCC)NCCC)=CC=C21 YXRBVSPNIQKGLW-UHFFFAOYSA-N 0.000 description 1
- NOTFYJXPXGAOFG-UHFFFAOYSA-N 1-(2,3-dihydro-1-benzofuran-5-yl)-n-propylpentan-2-amine;hydrochloride Chemical compound Cl.CCCNC(CCC)CC1=CC=C2OCCC2=C1 NOTFYJXPXGAOFG-UHFFFAOYSA-N 0.000 description 1
- WJVMBTJERYFQTM-UHFFFAOYSA-N 1-(2,3-dihydro-1h-inden-5-yl)-n-propylpentan-2-amine;hydrochloride Chemical compound Cl.CCCNC(CCC)CC1=CC=C2CCCC2=C1 WJVMBTJERYFQTM-UHFFFAOYSA-N 0.000 description 1
- WTMXZQWDONKXJR-UHFFFAOYSA-N 1-(5-chloro-1h-indol-3-yl)-n-propylpentan-2-amine;hydrochloride Chemical compound Cl.C1=C(Cl)C=C2C(CC(CCC)NCCC)=CNC2=C1 WTMXZQWDONKXJR-UHFFFAOYSA-N 0.000 description 1
- OPQKOIBVAAAOIY-UHFFFAOYSA-N 1-naphthalen-1-yl-n-propylpentan-2-amine Chemical compound C1=CC=C2C(CC(CCC)NCCC)=CC=CC2=C1 OPQKOIBVAAAOIY-UHFFFAOYSA-N 0.000 description 1
- UVZBFRKLBYYWOA-UHFFFAOYSA-N 1-naphthalen-2-yl-n-propylpentan-2-amine;hydrochloride Chemical compound Cl.C1=CC=CC2=CC(CC(CCC)NCCC)=CC=C21 UVZBFRKLBYYWOA-UHFFFAOYSA-N 0.000 description 1
- HDALNDAYCCNGCM-UHFFFAOYSA-N 1-naphthalen-2-ylpentan-2-amine;hydrochloride Chemical compound Cl.C1=CC=CC2=CC(CC(N)CCC)=CC=C21 HDALNDAYCCNGCM-UHFFFAOYSA-N 0.000 description 1
- MHIDNDHSCODSDV-UHFFFAOYSA-N 2-(2-nitropent-1-enyl)-1-benzofuran Chemical compound C1=CC=C2OC(C=C(CCC)[N+]([O-])=O)=CC2=C1 MHIDNDHSCODSDV-UHFFFAOYSA-N 0.000 description 1
- MOOYLICGVOJVNZ-UHFFFAOYSA-N 2-(2-nitropent-1-enyl)-1-benzothiophene Chemical compound C1=CC=C2SC(C=C(CCC)[N+]([O-])=O)=CC2=C1 MOOYLICGVOJVNZ-UHFFFAOYSA-N 0.000 description 1
- ZNQSMTQYSMPINX-UHFFFAOYSA-N 2-(2-nitropent-1-enyl)-1h-indole Chemical compound C1=CC=C2NC(C=C(CCC)[N+]([O-])=O)=CC2=C1 ZNQSMTQYSMPINX-UHFFFAOYSA-N 0.000 description 1
- KGPAZHWKLUUSBB-UHFFFAOYSA-N 2-(2-nitropent-1-enyl)naphthalene Chemical compound C1=CC=CC2=CC(C=C(CCC)[N+]([O-])=O)=CC=C21 KGPAZHWKLUUSBB-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
- VNDWQCSOSCCWIP-UHFFFAOYSA-N 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one Chemical compound C1=2C=CNC(=O)C=2C2=CC(F)=CC=C2C2=C1NC(C(C)(C)C)=N2 VNDWQCSOSCCWIP-UHFFFAOYSA-N 0.000 description 1
- WWKUHQMFXRAEPV-UHFFFAOYSA-N 3-(2-nitropent-1-enyl)-1-benzothiophene Chemical compound C1=CC=C2C(C=C(CCC)[N+]([O-])=O)=CSC2=C1 WWKUHQMFXRAEPV-UHFFFAOYSA-N 0.000 description 1
- FPCCSQOGAWCVBH-PSQIVULCSA-N 3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]-1,1,2,2-tetratritioethyl]-1h-quinazoline-2,4-dione Chemical compound O=C1NC2=CC=CC=C2C(=O)N1C([3H])([3H])C([3H])([3H])N(CC1)CCC1C(=O)C1=CC=C(F)C=C1 FPCCSQOGAWCVBH-PSQIVULCSA-N 0.000 description 1
- YUPVVZSYBUIDQR-UHFFFAOYSA-N 3-amino-1-(2-aminophenyl)propan-1-one;hydrobromide Chemical compound Br.NCCC(=O)C1=CC=CC=C1N YUPVVZSYBUIDQR-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- JUYWCNLKIARSLF-UHFFFAOYSA-N 4-(2-nitropent-1-enyl)-1,3-benzodioxole Chemical compound CCCC([N+]([O-])=O)=CC1=CC=CC2=C1OCO2 JUYWCNLKIARSLF-UHFFFAOYSA-N 0.000 description 1
- RXXVJDAXPWDCLP-UHFFFAOYSA-N 4-(2-nitropent-1-enyl)-1h-indole Chemical compound CCCC([N+]([O-])=O)=CC1=CC=CC2=C1C=CN2 RXXVJDAXPWDCLP-UHFFFAOYSA-N 0.000 description 1
- MGOLYGMJIQIYMW-UHFFFAOYSA-N 5-(2-nitropent-1-enyl)-2,3-dihydro-1-benzofuran Chemical compound CCCC([N+]([O-])=O)=CC1=CC=C2OCCC2=C1 MGOLYGMJIQIYMW-UHFFFAOYSA-N 0.000 description 1
- BQIMSOGUGKQCDV-UHFFFAOYSA-N 5-(2-nitropent-1-enyl)-2,3-dihydro-1h-indene Chemical compound CCCC([N+]([O-])=O)=CC1=CC=C2CCCC2=C1 BQIMSOGUGKQCDV-UHFFFAOYSA-N 0.000 description 1
- LLKFNPUXQZHIAE-UHFFFAOYSA-N 5-(3-aminopropyl)-8-bromo-3-methyl-2h-pyrazolo[4,3-c]quinolin-4-one Chemical compound O=C1N(CCCN)C2=CC=C(Br)C=C2C2=C1C(C)=NN2 LLKFNPUXQZHIAE-UHFFFAOYSA-N 0.000 description 1
- ORXDMPMHJAHNAP-UHFFFAOYSA-N 5-chloro-3-(2-nitropent-1-enyl)-1h-indole Chemical compound C1=C(Cl)C=C2C(C=C(CCC)[N+]([O-])=O)=CNC2=C1 ORXDMPMHJAHNAP-UHFFFAOYSA-N 0.000 description 1
- VAFVKRFDPSNZIJ-UHFFFAOYSA-N 6-(2-aminoethyl)-3h-1,3-benzoxazol-2-one Chemical class NCCC1=CC=C2NC(=O)OC2=C1 VAFVKRFDPSNZIJ-UHFFFAOYSA-N 0.000 description 1
- LOTJAPVZGSEGRH-UHFFFAOYSA-N 6-(2-nitropent-1-enyl)-2,3-dihydro-1,4-benzodioxine Chemical compound O1CCOC2=CC(C=C(CCC)[N+]([O-])=O)=CC=C21 LOTJAPVZGSEGRH-UHFFFAOYSA-N 0.000 description 1
- SQXGDXROBONBKK-UHFFFAOYSA-N 7-(2-nitropent-1-enyl)-1h-indole Chemical compound CCCC([N+]([O-])=O)=CC1=CC=CC2=C1NC=C2 SQXGDXROBONBKK-UHFFFAOYSA-N 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101150043532 CISH gene Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 241001191009 Gymnomyza Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000269435 Rana <genus> Species 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102220502023 Ubiquitin-like modifier-activating enzyme 1_H25N_mutation Human genes 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- XFXIJSRNFKHZFW-UHFFFAOYSA-N [Na].CCCCCCCC Chemical compound [Na].CCCCCCCC XFXIJSRNFKHZFW-UHFFFAOYSA-N 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940125713 antianxiety drug Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- CREXVNNSNOKDHW-UHFFFAOYSA-N azaniumylideneazanide Chemical group N[N] CREXVNNSNOKDHW-UHFFFAOYSA-N 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
- XNVWFBHTEBDKCA-UHFFFAOYSA-N butanedioic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CCC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O XNVWFBHTEBDKCA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 231100000153 central nervous system (CNS) toxicity Toxicity 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- UNXNGGMLCSMSLH-UHFFFAOYSA-N dihydrogen phosphate;triethylazanium Chemical compound OP(O)(O)=O.CCN(CC)CC UNXNGGMLCSMSLH-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000001614 effect on membrane Effects 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 1
- 229960005417 ketanserin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 150000002689 maleic acids Chemical class 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- KWKAKUADMBZCLK-UHFFFAOYSA-N methyl heptene Natural products CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- YKDRQFVYDRDQKU-UHFFFAOYSA-N n-[1-(1,3-benzodioxol-5-yl)pentan-2-yl]-4-methylaniline;hydrochloride Chemical compound Cl.C=1C=C2OCOC2=CC=1CC(CCC)NC1=CC=C(C)C=C1 YKDRQFVYDRDQKU-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 125000004971 nitroalkyl group Chemical group 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229940117803 phenethylamine Drugs 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 238000007745 plasma electrolytic oxidation reaction Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- PMZDQRJGMBOQBF-UHFFFAOYSA-N quinolin-4-ol Chemical compound C1=CC=C2C(O)=CC=NC2=C1 PMZDQRJGMBOQBF-UHFFFAOYSA-N 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 1
- 229950001675 spiperone Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C233/05—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/58—Radicals substituted by nitrogen atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24744597 | 1997-08-07 | ||
| PCT/JP1998/003468 WO1999007667A1 (en) | 1997-08-07 | 1998-08-03 | Novel ethylamine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI9820009A true SI9820009A (sl) | 1999-10-31 |
Family
ID=17163558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI9820009A SI9820009A (sl) | 1997-08-07 | 1998-08-03 | Novi etilaminski derivati |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6214859B1 (de) |
| EP (1) | EP0957080B1 (de) |
| JP (1) | JP4569980B2 (de) |
| KR (1) | KR100572900B1 (de) |
| CN (1) | CN1182103C (de) |
| AT (1) | ATE330930T1 (de) |
| AU (1) | AU747737B2 (de) |
| CA (1) | CA2267315C (de) |
| DE (1) | DE69835004T2 (de) |
| DK (1) | DK0957080T3 (de) |
| ES (1) | ES2267190T3 (de) |
| HU (1) | HU228759B1 (de) |
| IL (1) | IL129322A (de) |
| PT (1) | PT957080E (de) |
| SI (1) | SI9820009A (de) |
| WO (1) | WO1999007667A1 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4499208B2 (ja) | 1998-10-29 | 2010-07-07 | 株式会社フジモト・コーポレーション | 新規な光学活性アミノペンタン誘導体 |
| FR2792313A1 (fr) * | 1999-04-13 | 2000-10-20 | Synthelabo | Derives de 2-aminoethyl-indole, leur preparation et leur application en therapeutique |
| JP2003505369A (ja) * | 1999-07-15 | 2003-02-12 | エヌピーエス アレリックス コーポレーション | 偏頭痛を治療するための複素環式化合物 |
| JP4691230B2 (ja) * | 2000-04-11 | 2011-06-01 | 株式会社フジモト・コーポレーション | 光学活性１−（ベンゾフラン−２−イル）−２−プロピルアミノペンタンの製造方法 |
| SE0001438D0 (sv) * | 2000-04-18 | 2000-04-18 | Axon Chemicals Bv | New chemical compounds and their use in therapy |
| JP4888751B2 (ja) * | 2001-09-14 | 2012-02-29 | 株式会社フジモト・コーポレーション | トリフルオロプロピルアミノペンタン誘導体及びその製造方法 |
| JP4953041B2 (ja) * | 2001-09-19 | 2012-06-13 | 株式会社フジモト・コーポレーション | アポトーシス抑制剤 |
| US6991911B2 (en) * | 2003-12-15 | 2006-01-31 | Dade Behring Inc. | Assay for entactogens |
| US20050130243A1 (en) * | 2003-12-15 | 2005-06-16 | Zheng Yi F. | Assay for entactogens |
| US7022492B2 (en) * | 2003-12-15 | 2006-04-04 | Dade Behring Inc. | Ecstasy haptens and immunogens |
| US7037669B2 (en) * | 2004-03-22 | 2006-05-02 | Dade Behring Inc. | Assays for amphetamine and methamphetamine using stereospecific reagents |
| US7115383B2 (en) * | 2004-03-22 | 2006-10-03 | Dade Behring Inc. | Assays for amphetamine and methamphetamine |
| WO2007095187A2 (en) | 2006-02-13 | 2007-08-23 | Trustees Of Boston University | Compositions and methods for antibiotic potentiation and drug discovery |
| US20100137429A1 (en) * | 2007-06-21 | 2010-06-03 | Fujimoto Co., Ltd. | Composition for transdermal or transmucosal administration |
| US20130267552A1 (en) | 2012-04-04 | 2013-10-10 | IVAX International GmbH | Pharmaceutical compositions for combination therapy |
| EP3087984B1 (de) | 2013-12-25 | 2021-04-07 | Fujimoto Co., Ltd. | Prophylaktikum oder therapeutikum gegen aufmerksamkeitsdefizit-/hyperaktivitätsstörung |
| EP3226852B1 (de) | 2014-12-05 | 2020-03-18 | Semmelweis University | Arylalkylamin-verbindungen zur verwendung bei der vorbeugung oder behandlung von krebs |
| CN114028616A (zh) * | 2021-09-28 | 2022-02-11 | 遵义医科大学 | 一种用于牙槽骨缺损修复的组织工程化材料制备方法 |
| EP4590292A1 (de) * | 2022-09-21 | 2025-07-30 | Axsome Therapeutics, Inc. | Verbindungen und kombinationen davon zur behandlung neurologischer und psychiatrischer erkrankungen |
| WO2024108179A2 (en) * | 2022-11-18 | 2024-05-23 | Tactogen Inc | 2-ethylamine substituted benzofuran and benzothiophene compositions for mental disorders or enhancement |
| KR20250080790A (ko) | 2023-11-24 | 2025-06-05 | 충남대학교산학협력단 | 에틸아민 생산용 재조합 균주시스템 및 이를 이용한 에틸아민 생산 방법 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB855115A (en) * | 1958-07-11 | 1960-11-30 | Smith Kline French Lab | Improvements in or relating to ª‰-aminoalkylthianaphthene and ª‰-aminoalkylbenzofuran derivatives |
| GB901919A (en) * | 1959-02-12 | 1962-07-25 | Upjohn Co | Therapeutic compositions comprising alpha-alkyl-tryptamines |
| GB893707A (en) * | 1960-03-01 | 1962-04-11 | Roche Products Ltd | Novel tryptamine derivatives and a process for the manufacture thereof |
| FR1344579A (fr) * | 1961-11-23 | 1963-11-29 | Sandoz Sa | Nouveaux dérivés de l'indole et leur préparation |
| US3296072A (en) * | 1962-06-11 | 1967-01-03 | Upjohn Co | Method of treating mental depression |
| US3472870A (en) * | 1966-08-29 | 1969-10-14 | Mead Johnson & Co | Sulfonamidotryptamines |
| US3883560A (en) * | 1973-07-05 | 1975-05-13 | Colgate Palmolive Co | Salicylamidophenethanolamines |
| FR2536749A1 (fr) * | 1982-11-25 | 1984-06-01 | Cerm Cent Europ Rech Mauvernay | (amino-2 ethyl)-6 benzoxazolinones substituees, leur preparation et leurs applications en therapeutique |
| HU207280B (en) * | 1986-09-25 | 1993-03-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing new phenyl-alkyl-amines and pharmaceutical compositions containing them |
| US5220068A (en) * | 1986-09-25 | 1993-06-15 | Chinoin Gyogyszer - Es Vegyeszeti Termekek Gyara Rt. | Psychostimulant agent |
| TW270114B (de) * | 1993-10-22 | 1996-02-11 | Hoffmann La Roche | |
| US5627200A (en) | 1994-09-26 | 1997-05-06 | Pfizer Inc | β3 -Adrenoceptor agonists and antagonists for the treatment of intestinal motility disorders, depression, prostate disease and dyslipidemia |
| FR2729147A1 (fr) * | 1995-01-11 | 1996-07-12 | Adir | Nouveaux composes (hetero) cycliques alkyles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR2734816B1 (fr) * | 1995-05-31 | 1997-07-04 | Adir | Nouveaux aryl (alkyl) propylamides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR2734814B1 (fr) * | 1995-05-31 | 1997-07-04 | Adir | Nouveaux composes alkoxy-aryles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| GB9702310D0 (en) | 1997-02-05 | 1997-03-26 | Univ Hertfordshire | Invention |
-
1998
- 1998-08-03 AT AT98935352T patent/ATE330930T1/de active
- 1998-08-03 AU AU84635/98A patent/AU747737B2/en not_active Ceased
- 1998-08-03 IL IL12932298A patent/IL129322A/en not_active IP Right Cessation
- 1998-08-03 WO PCT/JP1998/003468 patent/WO1999007667A1/ja not_active Ceased
- 1998-08-03 US US09/269,718 patent/US6214859B1/en not_active Expired - Lifetime
- 1998-08-03 PT PT98935352T patent/PT957080E/pt unknown
- 1998-08-03 ES ES98935352T patent/ES2267190T3/es not_active Expired - Lifetime
- 1998-08-03 CA CA002267315A patent/CA2267315C/en not_active Expired - Fee Related
- 1998-08-03 JP JP51196699A patent/JP4569980B2/ja not_active Expired - Fee Related
- 1998-08-03 KR KR1019997003005A patent/KR100572900B1/ko not_active Expired - Fee Related
- 1998-08-03 DE DE69835004T patent/DE69835004T2/de not_active Expired - Lifetime
- 1998-08-03 EP EP98935352A patent/EP0957080B1/de not_active Expired - Lifetime
- 1998-08-03 DK DK98935352T patent/DK0957080T3/da active
- 1998-08-03 HU HU0001466A patent/HU228759B1/hu not_active IP Right Cessation
- 1998-08-03 CN CNB988011190A patent/CN1182103C/zh not_active Expired - Fee Related
- 1998-08-03 SI SI9820009A patent/SI9820009A/sl not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE69835004T2 (de) | 2007-03-01 |
| ES2267190T3 (es) | 2007-03-01 |
| HUP0001466A2 (hu) | 2001-05-28 |
| DE69835004D1 (de) | 2006-08-03 |
| US6214859B1 (en) | 2001-04-10 |
| WO1999007667A1 (en) | 1999-02-18 |
| JP4569980B2 (ja) | 2010-10-27 |
| HU228759B1 (en) | 2013-05-28 |
| CN1236356A (zh) | 1999-11-24 |
| HK1022682A1 (en) | 2000-08-18 |
| DK0957080T3 (da) | 2006-10-23 |
| ATE330930T1 (de) | 2006-07-15 |
| EP0957080B1 (de) | 2006-06-21 |
| CA2267315A1 (en) | 1999-02-18 |
| KR100572900B1 (ko) | 2006-04-24 |
| AU747737B2 (en) | 2002-05-23 |
| EP0957080A1 (de) | 1999-11-17 |
| KR20000068728A (ko) | 2000-11-25 |
| IL129322A0 (en) | 2000-02-17 |
| CA2267315C (en) | 2008-01-08 |
| EP0957080A4 (de) | 2004-10-20 |
| AU8463598A (en) | 1999-03-01 |
| PT957080E (pt) | 2006-10-31 |
| CN1182103C (zh) | 2004-12-29 |
| HUP0001466A3 (en) | 2001-09-28 |
| IL129322A (en) | 2004-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI9820009A (sl) | Novi etilaminski derivati | |
| AU710984B2 (en) | (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin -1-yl)-1-propanolmethanesulfonate trihydrate | |
| JPWO1999007667A1 (ja) | 新規なエチルアミン誘導体 | |
| US20070203120A1 (en) | Sulfonyl Substituted 1H-Indoles as Ligands for the 5-Hydroxytryptamine Receptors | |
| HU185475B (en) | Process for preparing /-/-n-methyl-3-/2-methyil-phenoxy/-3-phenyl-propyl-amine and salts thereof | |
| SK282944B6 (sk) | Tavené tropánové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie | |
| JP2020502184A (ja) | 疼痛および疼痛に関連する状態を処置するための新規なキノリンおよびイソキノリン誘導体 | |
| EP3344248B1 (de) | 6-gliedrige heterozyklen mit delta-opioidrezeptor-modulierenden verbindungen, verfahren zur herstellung und verwendung davon | |
| CZ2002441A3 (cs) | Substituované deriváty 1,5-dihydropyrrol-2-onu, způsob jejich výroby, léčiva tyto látky obsahující a jejich pouľití | |
| US7009051B2 (en) | 4-(2-pyridyl) piperazines having 5HT7 receptor agonist activity | |
| CZ64499A3 (cs) | Substituované 1,2,3,4-tetrahydro-2-dibenzofuranaminy a 2-aminocyklohepta[b]benzofurany | |
| US20200207759A1 (en) | New propanamine derivatives for treating pain and pain related conditions | |
| US8168646B2 (en) | 3,4-dihydroquinazoline derivatives | |
| US20130023566A1 (en) | 2-(1,2-benzisoxazol-3-yl)benzylamine derivatives | |
| AU762995B2 (en) | Novel optically active aminopentane derivative | |
| CA2222573A1 (en) | The use of alpha-1c-selective adrenoceptor agonists for the treatment of urinary incontinence | |
| KR100276994B1 (ko) | 아릴알콕시페녹시-이미다졸린화합물 | |
| TW317565B (de) | ||
| EP0940386A1 (de) | Benzozyclobutanverbindungen, deren Herstellungsverfahren und diese enthaltende pharmazeutische Zusammenstellungen | |
| CA2327513A1 (en) | N-aryloxyethyl-indoly-alkylamines for the treatment of depression | |
| Miasnik | The synthesis of conformationally restricted analogs of metaraminol and [alpha]-methyl-m?-tyramine | |
| US20030191314A1 (en) | Tetrahydroisoquinoline derivatives as modulators of dopamine D3 receptors | |
| HK1257927B (en) | 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | |
| MXPA00012609A (en) | 4,5,6 and 7-indole and indoline derivatives, their preparation and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| IF | Valid on the event date | ||
| OU01 | Decison according to article 73(1) ipa 1992, publication of decision on fulfilment of conditions on patentability |
Effective date: 20061122 |
|
| SP73 | Change of data on owner |
Owner name: FUJIMOTO CO., LTD.; JP Effective date: 20101020 |
|
| KO00 | Lapse of patent |
Effective date: 20150317 |